Mag Al Plus

Aluminum Hydroxide, Magnesium Hydroxide, And Dimethicone


Mckesson Corporation Dba As Sky Packaging
Human Otc Drug
NDC 63739-159
Mag Al Plus also known as Aluminum Hydroxide, Magnesium Hydroxide, And Dimethicone is a human otc drug labeled by 'Mckesson Corporation Dba As Sky Packaging'. National Drug Code (NDC) number for Mag Al Plus is 63739-159. This drug is available in dosage form of Suspension. The names of the active, medicinal ingredients in Mag Al Plus drug includes Aluminum Hydroxide - 200 mg/5mL Dimethicone - 20 mg/5mL Magnesium Hydroxide - 200 mg/5mL . The currest status of Mag Al Plus drug is Active.

Drug Information:

Drug NDC: 63739-159
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Mag Al Plus
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Otc Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Aluminum Hydroxide, Magnesium Hydroxide, And Dimethicone
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Mckesson Corporation Dba As Sky Packaging
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Suspension
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:ALUMINUM HYDROXIDE - 200 mg/5mL
DIMETHICONE - 20 mg/5mL
MAGNESIUM HYDROXIDE - 200 mg/5mL
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:ORAL
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: OTC MONOGRAPH FINAL
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 01 Jul, 2022
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 09 May, 2026
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Application Number: part331
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:McKesson Corporation dba as SKY Packaging
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
RxCUI:307746
The RxNorm Concept Unique Identifier. RxCUI is a unique number that describes a semantic concept about the drug product, including its ingredients, strength, and dose forms.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
NUI:N0000010282
Unique identifier applied to a drug concept within the National Drug File Reference Terminology (NDF-RT).
UNII:5QB0T2IUN0
92RU3N3Y1O
NBZ3QY004S
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.
Pharmacologic Class PE:Skin Barrier Activity [PE]
Physiologic effect or pharmacodynamic effect—tissue, organ, or organ system level functional activity—of the drug’s established pharmacologic class. Takes the form of the effect, followed by `[PE]` (such as `Increased Diuresis [PE]` or `Decreased Cytokine Activity [PE]`.
Pharmacologic Class:Calculi Dissolution Agent [EPC]
Increased Large Intestinal Motility [PE]
Inhibition Large Intestine Fluid/Electrolyte Absorption [PE]
Inhibition Small Intestine Fluid/Electrolyte Absorption [PE]
Magnesium Ion Exchange Activity [MoA]
Osmotic Activity [MoA]
Osmotic Laxative [EPC]
Skin Barrier Activity [PE]
Stimulation Large Intestine Fluid/Electrolyte Secretion [PE]
These are the reported pharmacological class categories corresponding to the SubstanceNames listed above.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
63739-159-1010 TRAY in 1 CASE (63739-159-10) / 10 CUP, UNIT-DOSE in 1 TRAY / 30 mL in 1 CUP, UNIT-DOSE (63739-159-77)01 Jul, 2022N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Purpose:

Active ingredients (in each 5 ml = 1 teaspoonful) purpose aluminum hydroxide (equiv. to dried gel, usp) 200 mg antacid magnesium hydroxide 200 mg antacid simethicone 20 mg antigas

Product Elements:

Mag al plus aluminum hydroxide, magnesium hydroxide, and dimethicone butylparaben propylparaben hypromellose 2910 (4000 mpa.s) propylene glycol sorbitol saccharin sodium peppermint oil water aluminum hydroxide aluminum hydroxide magnesium hydroxide magnesium cation hydroxide ion dimethicone dimethicone

Indications and Usage:

Uses for the relief of: acid indigestion heartburn sour stomach upset stomach due to these symptoms pressure and bloating commonly referred to as gas

Warnings:

Warnings do not take more than 16 teaspoonfuls in a 24-hour period or use the maximum dosage for more than 2 weeks except under the advice and supervision of a physician. ask a doctor before use if you have kidney disease a magnesium-restricted diet ask a doctor or pharmacist before use if you are presently taking a prescription drug. antacids may interact with certain prescription drugs. stop use and ask a doctor if symptoms last more than 2 weeks. keep out of reach of children.

Do Not Use:

Warnings do not take more than 16 teaspoonfuls in a 24-hour period or use the maximum dosage for more than 2 weeks except under the advice and supervision of a physician. ask a doctor before use if you have kidney disease a magnesium-restricted diet ask a doctor or pharmacist before use if you are presently taking a prescription drug. antacids may interact with certain prescription drugs. stop use and ask a doctor if symptoms last more than 2 weeks. keep out of reach of children.

Dosage and Administration:

Directions shake well before using do not take more than 16 teaspoonfuls in 24 hours or use the maximum dosage for more than 2 weeks adults and children 12 years and older take 2 to 4 teaspoonfuls four times a day or as directed by a physician children under 12 years consult a physician

Stop Use:

Stop use and ask a doctor if symptoms last more than 2 weeks.

Package Label Principal Display Panel:

Principal display panel - 30 ml dose cup tray label ndc 63739-159-77 mag-al plus antacid/ anti-gas sugar free each 30 ml contains: aluminum hydroxide 1200 mg magnesium hydroxide 1200 mg simethicone 120 mg shake well usual dosage: see attached drug facts store at 20° to 25°c (68° to 77°f) [see usp controlled room temperature]. protect from freezing. for institutional use only 10 x 30 ml unit-dose cups dist. by: mckesson corporation dba sky packaging memphis, tn 38141 t1761c300322 iss. 03/2022 principal display panel - 30 ml dose cup tray label

Further Questions:

Questions or comments? call 1-800-845-8210


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.